Targeted Therapies for Each Subtype of Breast Cancer

Abstract

Breast cancer (BC) is a clinically heterogeneous malignancy and a leading cause of cancer-related mortality in women worldwide. It is classified into hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-positive, and triple-negative (TNBC) subtypes based on molecular biomarkers. This heterogeneity drives distinct disease progression and treatment responses, making subtype-specific precision therapy indispensable for improving patient outcomes. While estrogen receptor (ER)-targeting agents and anti-HER2 therapies have achieved notable successes, critical challenges remain, including drug resistance, inadequate biomarkers, and limited therapeutic targets for TNBC. This review comprehensively summarizes recent advances in targeted therapies for major BC subtypes: endocrine therapy combined with cyclin-dependent kinase 4/6 (CDK4/6) or phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) inhibitors for HR-positive BC; novel antibody‒drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd) and tyrosine kinase inhibitors (TKIs) for HER2-positive BC; and trophoblast cell-surface antigen 2 (Trop-2) ADCs, immunotherapies, and poly-ADP-ribose polymerase (PARP) inhibitors for TNBC. It also discusses cross-subtype therapeutic platforms (ADCs, PI3K/AKT/mTOR pathway) and emerging modalities (chimeric antigen receptor [CAR] T-cell therapy, proteolysis-targeting chimeras [PROTACs]). By analyzing successes, challenges, and translational potential, this review provides a clear framework for clinicians and researchers, advancing personalized treatment optimization and addressing unmet clinical needs in BC precision oncology.

Keywords

breast cancer / estrogen receptor targeted therapy / human epidermal growth factor receptor 2 / progesterone receptor / triple-negative breast cancer

References

[1] F. Bray, M. Laversanne, H. Sung, et al., “Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 74 (2024): 229–263.

[2] S. Loibl, P. Poortmans, M. Morrow, C. Denkert, and G. Curigliano, “Breast Cancer,” Lancet 397 (2021): 1750–1769.

[3] X. Xiong, L. W. Zheng, Y. Ding, et al., “Breast Cancer: Pathogenesis and Treatments,” Signal Transduction and Targeted Therapy 10 (2025): 49.

[4] D. A. Berry, C. Cirrincione, I. C. Henderson, et al., “Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer,” JAMA 295 (2006): 1658–1667.

[5] S. Loibl and L. Gianni, “HER2-Positive Breast Cancer,” Lancet 389 (2017): 2415–2429.

[6] S. H. Giordano, M. A. B. Franzoi, S. Temin, et al., “Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update,” Journal of Clinical Oncology 40 (2022): 2612–2635.

[7] S. Kunte, J. Abraham, and A. J. Montero, “Novel HER2-Targeted Therapies for HER2-Positive Metastatic Breast Cancer,” Cancer 126 (2020): 4278–4288.

[8] J. Veeraraghavan, C. De Angelis, C. Gutierrez, et al., “HER2-Positive Breast Cancer Treatment and Resistance,” Advances in Experimental Medicine and Biology 1464 (2025): 495–525.

[9] Y. He, Z. Jiang, C. Chen, and X. Wang, “Classification of Triple-Negative Breast Cancers Based on Immunogenomic Profiling,” Journal of Experimental & Clinical Cancer Research 37 (2018): 327.

[10] S. Y. Wu, H. Wang, Z. M. Shao, and Y. Z. Jiang, “Triple-Negative Breast Cancer: New Treatment Strategies in the Era of Precision Medicine,” Science China Life Sciences 64 (2021): 372–388.

[11] H. Jie, W. Ma, and C. Huang, “Diagnosis, Prognosis, and Treatment of Triple-Negative Breast Cancer: A Review,” Breast Cancer 17 (2025): 265–274.

[12] R. Ran, X. Chen, J. Yang, and B. Xu, “Immunotherapy in Breast Cancer: Current Landscape and Emerging Trends,” Experimental Hematology & Oncology 14 (2025): 77.

[13] Z. Chen, Y. Liu, M. Lyu, et al., “Classifications of Triple-Negative Breast Cancer: Insights and Current Therapeutic Approaches,” Cell & Bioscience 15 (2025): 13.

[14] A. C. Wolff, M. E. Hammond, D. G. Hicks, et al., “Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update,” Journal of Clinical Oncology 31 (2013): 3997–4013.

[15] K. Polyak, “Heterogeneity in Breast Cancer,” Journal of Clinical Investigation 121 (2011): 3786–3788.

[16] S. Nagini, “Breast Cancer: Current Molecular Therapeutic Targets and New Players,” Anti-Cancer Agents in Medicinal Chemistry 17 (2017): 152–163.

[17] H. K. Patel and T. Bihani, “Selective Estrogen Receptor Modulators (SERMs) and Selective Estrogen Receptor Degraders (SERDs) in Cancer Treatment,” Pharmacology & Therapeutics 186 (2018): 1–24.

[18] A. R. Tan, S. A. Im, A. Mattar, et al., “Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection Plus Chemotherapy in HER2-Positive Early Breast Cancer (FeDeriCa): A Randomised, Open-Label, Multicentre, Non-Inferiority, Phase 3 Study,” Lancet Oncology 22 (2021): 85–97.

[19] G. Y. Wu, M. Z. Xiao, W. C. Hao, et al., “Drug Resistance in Breast Cancer: Mechanisms and Strategies for Management,” Drug Resistance Updates 83 (2025): 101288.

[20] S. Lobo-Martins, L. Arecco, T. P. Cabral, et al., “Extended Adjuvant Endocrine Therapy in Early Breast Cancer: Finding the Individual Balance,” ESMO Open 10 (2025): 105057.

[21] Early Breast Cancer Trialists' Collaborative Group (EBCTCG). “Aromatase Inhibitors Versus Tamoxifen in Early Breast Cancer: Patient-Level Meta-Analysis of the Randomised Trials,” Lancet 386 (2015) 1341–1352.

[22] Early Breast Cancer Trialists' Collaborative Group (EBCTCG), “Aromatase Inhibitors Versus Tamoxifen in Premenopausal Women With Oestrogen Receptor-Positive Early-Stage Breast Cancer Treated With Ovarian Suppression: A Patient-Level Meta-Analysis of 7030 Women From Four Randomised Trials,” Lancet Oncology 23 (2022) 382–392.

[23] Y. Shieh and J. A. Tice, “Medications for Primary Prevention of Breast Cancer,” JAMA 324 (2020): 291–292.

[24] J. M. Nabholtz, “Long-Term Safety of Aromatase Inhibitors in the Treatment of Breast Cancer,” Therapeutics and Clinical Risk Management 4 (2008): 189–204.

[25] S. Nardin, B. Ruffilli, T. L. Landolfo, et al., “Aromatase Inhibitors as Adjuvant Therapy in Early Breast Cancer: Insights Into Toxicities and Their Management,” Cancers 17 (2025): 2726.

[26] N. C. Turner, C. Swift, L. Kilburn, et al., “ESR1 Mutations and Overall Survival on Fulvestrant Versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials,” Clinical Cancer Research 26 (2020): 5172–5177.

[27] R. S. Mehta, W. E. Barlow, K. S. Albain, et al., “Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer,” New England Journal of Medicine 367 (2012): 435–444.

[28] A. Gombos, A. Goncalves, G. Curigliano, et al., “How I Treat Endocrine-Dependent Metastatic Breast Cancer,” ESMO Open 8 (2023): 100882.

[29] F. C. Bidard, V. G. Kaklamani, P. Neven, et al., “Elacestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial,” Journal of Clinical Oncology 40 (2022): 3246–3256.

[30] K. L. Jhaveri, P. Neven, M. L. Casalnuovo, et al., “Imlunestrant With or Without Abemaciclib in Advanced Breast Cancer,” New England Journal of Medicine 392 (2025): 1189–1202.

[31] M. Campone, M. De Laurentiis, K. Jhaveri, et al., “Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer,” New England Journal of Medicine 393, no. 6 (2025): 556–568.

[32] P. J. Roberts, J. E. Bisi, J. C. Strum, et al., “Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy,” Journal of the National Cancer Institute 104 (2012): 476–487.

[33] E. A. Musgrove, C. S. Lee, M. F. Buckley, and R. L. Sutherland, “Cyclin D1 Induction in Breast Cancer Cells Shortens G1 and Is Sufficient for Cells Arrested in G1 to Complete the Cell Cycle,” Proceedings of the National Academy of Sciences of the United States of America 91 (1994): 8022–8026.

[34] R. S. Finn, M. Martin, H. S. Rugo, et al., “Palbociclib and Letrozole in Advanced Breast Cancer,” New England Journal of Medicine 375 (2016): 1925–1936.

[35] N. C. Turner, D. J. Slamon, J. Ro, et al., “Overall Survival With Palbociclib and Fulvestrant in Advanced Breast Cancer,” New England Journal of Medicine 379 (2018): 1926–1936.

[36] G. N. Hortobagyi, S. M. Stemmer, H. A. Burris, et al., “Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer,” New England Journal of Medicine 375 (2016): 1738–1748.

[37] D. J. Slamon, P. Neven, S. Chia, et al., “Overall Survival With Ribociclib Plus Fulvestrant in Advanced Breast Cancer,” New England Journal of Medicine 382 (2020): 514–524.

[38] D. Tripathy, S. A. Im, M. Colleoni, et al., “Ribociclib Plus Endocrine Therapy for Premenopausal Women With Hormone-Receptor-Positive, Advanced Breast Cancer (MONALEESA-7): A Randomised Phase 3 Trial,” Lancet Oncology 19 (2018): 904–915.

[39] D. Slamon, O. Lipatov, Z. Nowecki, et al., “Ribociclib Plus Endocrine Therapy in Early Breast Cancer,” New England Journal of Medicine 390 (2024): 1080–1091.

[40] M. N. Dickler, S. M. Tolaney, H. S. Rugo, et al., “MONARCH 1, a Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients With Refractory HR⁺/HER2⁻ Metastatic Breast Cancer,” Clinical Cancer Research 23 (2017): 5218–5224.

[41] M. P. Goetz, M. Toi, M. Campone, et al., “MONARCH 3: Abemaciclib as Initial Therapy for Advanced Breast Cancer,” Journal of Clinical Oncology 35 (2017): 3638–3646.

[42] G. W. Sledge, M. Toi, P. Neven, et al., “MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR⁺/HER2⁻ Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy,” Journal of Clinical Oncology 35 (2017): 2875–2884.

[43] S. R. D. Johnston, N. Harbeck, R. Hegg, et al., “Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR⁺, HER2⁻, Node-Positive, High-Risk, Early Breast Cancer (monarchE),” Journal of Clinical Oncology 38 (2020): 3987–3998.

[44] B. Xu, Q. Zhang, P. Zhang, et al., “Dalpiciclib or Placebo Plus Fulvestrant in Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer: A Randomized, Phase 3 Trial,” Nature Medicine 27 (2021): 1904–1909.

[45] P. Zhang, Q. Zhang, Z. Tong, et al., “Dalpiciclib Plus Letrozole or Anastrozole Versus Placebo Plus Letrozole or Anastrozole as First-Line Treatment in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (DAWNA-2): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial,” Lancet Oncology 24 (2023): 646–657.

[46] R. S. Finn, J. P. Crown, I. Lang, et al., “The Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib in Combination With Letrozole Versus Letrozole Alone as First-line Treatment of Oestrogen Receptor-Positive, HER2-Negative, Advanced Breast Cancer (PALOMA-1/TRIO-18): A Randomised Phase 2 Study,” Lancet Oncology 16 (2015): 25–35.

[47] E. L. Mayer, A. C. Dueck, M. Martin, et al., “Palbociclib With Adjuvant Endocrine Therapy in Early Breast Cancer (PALLAS): Interim Analysis of a Multicentre, Open-Label, Randomised, Phase 3 Study,” Lancet Oncology 22 (2021): 212–222.

[48] S. Loibl, F. Marmé, M. Martin, et al., “Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial,” Journal of Clinical Oncology 39 (2021): 1518–1530.

[49] P. Rastogi, J. O'Shaughnessy, M. Martin, et al., “Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes,” Journal of Clinical Oncology 42 (2024): 987–993.

[50] S. Johnston, M. Martin, J. O'Shaughnessy, et al., “Overall Survival With Abemaciclib in Early Breast Cancer,” Annals of Oncology 37, no. 2 (2025): 155–165.

[51] T. W. Miller, B. N. Rexer, J. T. Garrett, and C. L. Arteaga, “Mutations in the Phosphatidylinositol 3-Kinase Pathway: Role in Tumor Progression and Therapeutic Implications in Breast Cancer,” Breast Cancer Research 13 (2011): 224.

[52] J. A. Engelman, “Targeting PI3K Signalling in Cancer: Opportunities, Challenges and Limitations,” Nature Reviews Cancer 9 (2009): 550–562.

[53] P. Razavi, M. T. Chang, G. Xu, et al., “The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers,” Cancer Cell 34 (2018): 427–438.e426.

[54] T. W. Miller, B. T. Hennessy, A. M. González-Angulo, et al., “Hyperactivation of Phosphatidylinositol-3 Kinase Promotes Escape From Hormone Dependence in Estrogen Receptor-Positive Human Breast Cancer,” Journal of Clinical Investigation 120 (2010): 2406–2413.

[55] K. Cerma, F. Piacentini, L. Moscetti, et al., “Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges,” Biomedicines 11 (2023): 109.

[56] J. T. Beck, G. N. Hortobagyi, M. Campone, et al., “Everolimus Plus Exemestane as First-Line Therapy in HR⁺, HER2⁻ Advanced Breast Cancer in BOLERO-2,” Breast Cancer Research and Treatment 143 (2014): 459–467.

[57] C. Arena, M. E. Bizzoca, V. C. A. Caponio, et al., “Everolimus Therapy and Side‑Effects: A Systematic Review and Meta‑Analysis,” International Journal of Oncology 59 (2021): 54.

[58] F. André, E. Ciruelos, G. Rubovszky, et al., “Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer,” New England Journal of Medicine 380 (2019): 1929–1940.

[59] F. André, E. M. Ciruelos, D. Juric, et al., “Alpelisib Plus Fulvestrant for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Final Overall Survival Results From SOLAR-1,” Annals of Oncology 32 (2021): 208–217.

[60] K. L. Jhaveri, S. A. Im, C. Saura, et al., “Overall Survival With Inavolisib in PIK3CA-Mutated Advanced Breast Cancer,” New England Journal of Medicine 393, no. 2 (2025): 151–161.

[61] N. C. Turner, S. A. Im, C. Saura, et al., “Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer,” New England Journal of Medicine 391 (2024): 1584–1596.

[62] N. C. Turner, E. Alarcón, A. C. Armstrong, et al., “BEECH: A Dose-Finding Run-In Followed by a Randomised Phase II Study Assessing the Efficacy of AKT Inhibitor Capivasertib (AZD5363) Combined With Paclitaxel in Patients With Estrogen Receptor-Positive Advanced or Metastatic Breast Cancer, and in a PIK3CA Mutant Sub-Population,” Annals of Oncology 30 (2019): 774–780.

[63] S. B. Kim, R. Dent, S. A. Im, et al., “Ipatasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel as First-Line Therapy for Metastatic Triple-Negative Breast Cancer (LOTUS): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial,” Lancet Oncology 18 (2017): 1360–1372.

[64] N. C. Turner, M. Oliveira, S. J. Howell, et al., “Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer,” New England Journal of Medicine 388 (2023): 2058–2070.

[65] A. K. Voss and T. Thomas, “Histone Lysine and Genomic Targets of Histone Acetyltransferases in Mammals,” BioEssays 40 (2018): e1800078.

[66] X. Yang, D. L. Phillips, A. T. Ferguson, W. G. Nelson, J. G. Herman, and N. E. Davidson, “Synergistic Activation of Functional Estrogen Receptor (ER)-α by DNA Methyltransferase and Histone Deacetylase Inhibition in Human ER-α-Negative Breast Cancer Cells,” Cancer Research 61 (2001): 7025–7029.

[67] H. Kawai, H. Li, S. Avraham, S. Jiang, and H. K. Avraham, “Overexpression of Histone Deacetylase HDAC1 Modulates Breast Cancer Progression by Negative Regulation of Estrogen Receptor α,” International Journal of Cancer 107 (2003): 353–358.

[68] D. A. Yardley, R. R. Ismail-Khan, B. Melichar, et al., “Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Wwithout Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor,” Journal of Clinical Oncology 31 (2013): 2128–2135.

[69] R. M. Connolly, F. Zhao, K. D. Miller, et al., “E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group,” Journal of Clinical Oncology 39 (2021): 3171–3181.

[70] B. Xu, Q. Zhang, X. Hu, et al., “Entinostat, a Class I Selective Histone Deacetylase Inhibitor, Plus Exemestane for Chinese Patients With Hormone Receptor-Positive Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial,” Acta Pharmaceutica Sinica B 13 (2023): 2250–2258.

[71] P. N. Munster, K. T. Thurn, S. Thomas, et al., “A Phase II Study of the Histone Deacetylase Inhibitor Vorinostat Combined With Tamoxifen for the Treatment of Patients With Hormone Therapy-Resistant Breast Cancer,” British Journal of Cancer 104 (2011): 1828–1835.

[72] A. Purohit, L. W. Woo, and B. V. Potter, “Steroid Sulfatase: A Pivotal Player in Estrogen Synthesis and Metabolism,” Molecular and Cellular Endocrinology 340 (2011): 154–160.

[73] S. J. Stanway, P. Delavault, A. Purohit, et al., “Steroid Sulfatase: A New Target for the Endocrine Therapy of Breast Cancer,” Oncologist 12 (2007): 370–374.

[74] C. Palmieri, R. C. Stein, X. Liu, et al., “IRIS Study: A Phase II Study of the Steroid Sulfatase Inhibitor Irosustat When Added to an Aromatase Inhibitor in ER-Positive Breast Cancer Patients,” Breast Cancer Research and Treatment 165 (2017): 343–353.

[75] C. Palmieri, H. Linden, S. N. Birrell, et al., “Activity and Safety of Enobosarm, a Novel, Oral, Selective Androgen Receptor Modulator, in Androgen Receptor-Positive, Oestrogen Receptor-Positive, and HER2-Negative Advanced Breast Cancer (Study G200802): A Randomised, Open-Label, Multicentre, Multinational, Parallel Design, Phase 2 Trial,” Lancet Oncology 25 (2024): 317–325.

[76] I. Krop, V. Abramson, M. Colleoni, et al., “A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane With or Without Enzalutamide in Patients With Hormone Receptor-Positive Breast Cancer,” Clinical Cancer Research 26 (2020): 6149–6157.

[77] M. Royce, M. Shah, L. Zhang, et al., “FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients With Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer,” Clinical Cancer Research 31 (2025): 4405–4411.

[78] L. J. C. Oliveira, M. S. Mano, C. Barrios, and R. Dienstmann, “The Promise of ctDNA-Based, Molecularly-Driven Early Switch Therapy From PADA-1 to SERENA-6,” Breast Cancer Research and Treatment 215 (2025): 5.

[79] D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire, “Human Breast Cancer: Correlation of Relapse and Survival With Amplification of the HER-2/Neu Oncogene,” Science 235 (1987): 177–182.

[80] L. Gianni, W. Eiermann, V. Semiglazov, et al., “Neoadjuvant Chemotherapy With Trastuzumab Followed by Adjuvant Trastuzumab Versus Neoadjuvant Chemotherapy Alone, in Patients With HER2-Positive Locally Advanced Breast Cancer (the NOAH Trial): A Randomised Controlled Superiority Trial With a Parallel HER2-Negative Cohort,” Lancet 375 (2010): 377–384.

[81] M. J. Piccart-Gebhart, M. Procter, B. Leyland-Jones, et al., “Trastuzumab After Adjuvant Chemotherapy in HER2-Positive Breast Cancer,” New England Journal of Medicine 353 (2005): 1659–1672.

[82] E. A. Perez, E. H. Romond, V. J. Suman, et al., “Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831,” Journal of Clinical Oncology 32 (2014): 3744–3752.

[83] D. J. Slamon, B. Leyland-Jones, S. Shak, et al., “Use of Chemotherapy Plus a Monoclonal Antibody Against HER2 for Metastatic Breast Cancer That Overexpresses HER2,” New England Journal of Medicine 344 (2001): 783–792.

[84] L. Gianni, T. Pienkowski, Y. H. Im, et al., “Efficacy and Safety of Neoadjuvant Pertuzumab and Trastuzumab in Women With Locally Advanced, Inflammatory, or Early HER2-Positive Breast Cancer (NeoSphere): A Randomised Multicentre, Open-Label, Phase 2 Trial,” Lancet Oncology 13 (2012): 25–32.

[85] G. von Minckwitz, M. Procter, E. de Azambuja, et al., “Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer,” New England Journal of Medicine 377 (2017): 122–131.

[86] S. M. Swain, J. Baselga, S. B. Kim, et al., “Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer,” New England Journal of Medicine 372 (2015): 724–734.

[87] H. S. Rugo, S. A. Im, F. Cardoso, et al., “Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial,” JAMA Oncology 7 (2021): 573–584.

[88] G. von Minckwitz, C. S. Huang, M. S. Mano, et al., “Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer,” New England Journal of Medicine 380 (2019): 617–628.

[89] S. Verma, D. Miles, L. Gianni, et al., “Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer,” New England Journal of Medicine 367 (2012): 1783–1791.

[90] C. Saura, S. Modi, I. Krop, et al., “Trastuzumab Deruxtecan in Previously Treated Patients With HER2-Positive Metastatic Breast Cancer: Updated Survival Results From a Phase II Trial (DESTINY-Breast01),” Annals of Oncology 35 (2024): 302–307.

[91] F. André, Y. Hee Park, S. B. Kim, et al., “Trastuzumab Deruxtecan Versus Treatment of Physician's Choice in Patients With HER2-Positive Metastatic Breast Cancer (DESTINY-Breast02): A Randomised, Open-Label, Multicentre, Phase 3 Trial,” Lancet 401 (2023): 1773–1785.

[92] K. Tamura, J. Tsurutani, S. Takahashi, et al., “Trastuzumab Deruxtecan (DS-8201a) in Patients with Advanced HER2-Positive Breast Cancer Previously Treated With Trastuzumab Emtansine: A Dose-Expansion, Phase 1 Study,” Lancet Oncology 20 (2019): 816–826.

[93] S. Modi, W. Jacot, T. Yamashita, et al., “Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer,” New England Journal of Medicine 387 (2022): 9–20.

[94] A. Bardia, X. Hu, R. Dent, et al., “Trastuzumab Deruxtecan After Endocrine Therapy in Metastatic Breast Cancer,” New England Journal of Medicine 391 (2024): 2110–2122.

[95] S. Loibl, Y. H. Park, Z. Shao, et al., “Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer,” New England Journal of Medicine 394, no. 9 (2025): 845–857.

[96] S. M. Tolaney, Z. Jiang, Q. Zhang, et al., “Trastuzumab Deruxtecan Plus Pertuzumab for HER2-Positive Metastatic Breast Cancer,” New England Journal of Medicine 394 (2025): 551–562.

[97] N. Harbeck, S. Modi, L. Pusztai, et al., “DESTINY-Breast11: Neoadjuvant Trastuzumab Deruxtecan Alone (T-DXd) or Followed by Paclitaxel + Trastuzumab + Pertuzumab (T-DXd-THP) vs SOC for High-Risk HER2+ Early Breast Cancer (eBC),” paper presented at ESMO Congress 2025, Berlin, Germany, October 18, 2025.

[98] C. E. Geyer, J. Forster, D. Lindquist, et al., “Lapatinib Plus Capecitabine for HER2-Positive Advanced Breast Cancer,” New England Journal of Medicine 355 (2006): 2733–2743.

[99] A. Chan, S. Delaloge, F. A. Holmes, et al., “Neratinib After Trastuzumab-Based Adjuvant Therapy in Patients With HER2-Positive Breast Cancer (ExteNET): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial,” Lancet Oncology 17 (2016): 367–377.

[100] C. Saura, M. Oliveira, Y. H. Feng, et al., “Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial,” Journal of Clinical Oncology 38 (2020): 3138–3149.

[101] B. Xu, M. Yan, F. Ma, et al., “Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer (PHOEBE): A Multicentre, Open-Label, Randomised, Controlled, Phase 3 Trial,” Lancet Oncology 22 (2021): 351–360.

[102] F. Cao, Z. Ma, Z. Wu, et al., “Pyrotinib After Trastuzumab-Based Adjuvant Therapy in Patients With HER2-Positive Breast Cancer (PERSIST): A Multicenter Phase II Trial,” eLife 13 (2025): RP101724.

[103] N. U. Lin, R. K. Murthy, V. Abramson, et al., “Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial,” JAMA Oncology 9 (2023): 197–205.

[104] J. Baselga, “Treatment of HER2-Overexpressing Breast Cancer,” Annals of Oncology 21, no. Suppl 7 (2010): vii36–vii40.

[105] R. Nahta and F. J. Esteva, “Herceptin: Mechanisms of Action and Resistance,” Cancer Letters 232 (2006): 123–138.

[106] J. A. Drebin, V. C. Link, and M. I. Greene, “Monoclonal Antibodies Reactive With Distinct Domains of the Neu Oncogene-Encoded p185 Molecule Exert Synergistic Anti-Tumor Effects In Vivo,” Oncogene 2 (1988): 273–277.

[107] K. Ishii, N. Morii, and H. Yamashiro, “Pertuzumab in the Treatment of HER2-Positive Breast Cancer: An Evidence-Based Review of Its Safety, Efficacy, and Place in Therapy,” Core Evidence 14 (2019): 51–70.

[108] A. G. Waks, E. L. Chen, N. Graham, et al., “Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT Trial),” JCO Oncology Practice 21 (2025): 351–357.

[109] C. Jackisch, D. Stroyakovskiy, X. Pivot, et al., “Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial,” JAMA Oncology 5 (2019): e190339.

[110] J. B. Stavenhagen, S. Gorlatov, N. Tuaillon, et al., “Fc Optimization of Therapeutic Antibodies Enhances Their Ability to Kill Tumor Cells In Vitro and Controls Tumor Expansion In Vivo via Low-Affinity Activating Fcγ Receptors,” Cancer Research 67 (2007): 8882–8890.

[111] H. S. Rugo, S. A. Im, F. Cardoso, et al., “Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial,” Journal of Clinical Oncology 41 (2023): 198–205.

[112] L. Christl, FDA's Overview of the Regulatory Guidance for the Development and Approval of Biosimilar Products in the US, https://www.fda.gov/files/drugs/published/FDA’s-Overview-of-the-Regulatory-Guidance-for-the-Development-and-Approval-of-Biosimilar-Products-in-the-US.pdf.

[113] E. Triantafyllidi and J. K. Triantafillidis, “Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer,” Biomedicines 10 (2022): 2045.

[114] A. Oliva, C. Scavone, C. Riccardi, F. F. Bernardi, F. Salvo, and A. Mascolo, “Safety Profile of Trastuzumab Originator vs Biosimilars: A Systematic Review and Meta-Analysis of Randomized Clinical Trials,” Clinical & Translational Oncology 27 (2025): 1826–1838.

[115] L. P. Díaz, S. Millán, N. Chaban, A. D. Campo, and E. Spitzer, “Current State and Comparison of the Clinical Development of Bevacizumab, Rituximab and Trastuzumab Biosimilars,” Future Oncology 17 (2021): 2529–2544.

[116] A. Beck, L. Goetsch, C. Dumontet, and N. Corvaïa, “Strategies and Challenges for the Next Generation of Antibody-Drug Conjugates,” Nature Reviews Drug Discovery 16 (2017): 315–337.

[117] G. D. Lewis Phillips, G. Li, D. L. Dugger, et al., “Targeting HER2-Positive Breast Cancer With Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate,” Cancer Research 68 (2008): 9280–9290.

[118] T. T. Junttila, G. Li, K. Parsons, G. L. Phillips, and M. X. Sliwkowski, “Trastuzumab-DM1 (T-DM1) Retains All the Mechanisms of Action of Trastuzumab and Efficiently Inhibits Growth of Lapatinib Insensitive Breast Cancer,” Breast Cancer Research and Treatment 128 (2011): 347–356.

[119] I. E. Krop, S. A. Im, C. Barrios, et al., “Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study,” Journal of Clinical Oncology 40 (2022): 438–448.

[120] F. Montemurro, S. Delaloge, C. H. Barrios, et al., “Trastuzumab Emtansine (T-DM1) in Patients with HER2-Positive Metastatic Breast Cancer and Brain Metastases: Exploratory Final Analysis of Cohort 1 From KAMILLA, a Single-Arm Phase IIIb Clinical Trial,” Annals of Oncology 31 (2020): 1350–1358.

[121] A. Yver, T. Agatsuma, and J. C. Soria, “The Art of Innovation: Clinical Development of Trastuzumab Deruxtecan and Redefining How Antibody‒Drug Conjugates Target HER2-Positive Cancers,” Annals of Oncology 31 (2020): 430–434.

[122] N. Harbeck, E. Ciruelos, G. Jerusalem, et al., “Trastuzumab Deruxtecan in HER2-Positive Advanced Breast Cancer With or Without Brain Metastases: A Phase 3b/4 Trial,” Nature Medicine 30 (2024): 3717–3727.

[123] T. Yamaoka, S. Kusumoto, K. Ando, M. Ohba, and T. Ohmori, “Receptor Tyrosine Kinase-Targeted Cancer Therapy,” International Journal of Molecular Sciences 19 (2018): 3491.

[124] W. Xia, I. Husain, L. Liu, et al., “Lapatinib Antitumor Activity Is Not Dependent Upon Phosphatase and Tensin Homologue Deleted on Chromosome 10 in ErbB2-Overexpressing Breast Cancers,” Cancer Research 67 (2007): 1170–1175.

[125] M. Scaltriti, F. Rojo, A. Ocaña, et al., “Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer,” Journal of the National Cancer Institute 99 (2007): 628–638.

[126] G. E. Konecny, M. D. Pegram, N. Venkatesan, et al., “Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) Against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells,” Cancer Research 66 (2006): 1630–1639.

[127] I. Schlam and S. M. Swain, “HER2-Positive Breast Cancer and Tyrosine Kinase Inhibitors: The Time Is Now,” npj Breast Cancer 7 (2021): 56.

[128] N. U. Lin and E. P. Winer, “Brain Metastases: The HER2 Paradigm,” Clinical Cancer Research 13 (2007): 1648–1655.

[129] T. Bachelot, G. Romieu, M. Campone, et al., “Lapatinib Plus Capecitabine in Patients With Previously Untreated Brain Metastases From HER2-Positive Metastatic Breast Cancer (LANDSCAPE): A Single-Group Phase 2 Study,” Lancet Oncology 14 (2013): 64–71.

[130] N. U. Lin, V. Diéras, D. Paul, et al., “Multicenter Phase II Study of Lapatinib in Patients With Brain Metastases From HER2-Positive Breast Cancer,” Clinical Cancer Research 15 (2009): 1452–1459.

[131] D. M. Collins, N. T. Conlon, S. Kannan, et al., “Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared With Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer,” Cancers 11 (2019): 737.

[132] A. Canonici, M. Gijsen, M. Mullooly, et al., “Neratinib Overcomes Trastuzumab Resistance in HER2 Amplified Breast Cancer,” Oncotarget 4 (2013): 1592–1605.

[133] A. Chan, B. Moy, J. Mansi, et al., “Final Efficacy Results of Neratinib in HER2-Positive Hormone Receptor-Positive Early-Stage Breast Cancer From the Phase III ExteNET Trial,” Clinical Breast Cancer 21 (2021): 80–91.e87.

[134] J. Wu, Z. Jiang, Z. Liu, et al., “Neoadjuvant Pyrotinib, Trastuzumab, and Docetaxel for HER2-Positive Breast Cancer (PHEDRA): A Double-Blind, Randomized Phase 3 Trial,” BMC Medicine 20 (2022): 498.

[135] A. Kulukian, P. Lee, J. Taylor, et al., “Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination With Trastuzumab or Docetaxel in Solid Tumor Models,” Molecular Cancer Therapeutics 19 (2020): 976–987.

[136] R. Duchnowska, S. Loibl, and J. Jassem, “Tyrosine Kinase Inhibitors for Brain Metastases in HER2-Positive Breast Cancer,” Cancer Treatment Reviews 67 (2018): 71–77.

[137] R. K. Murthy, S. Loi, A. Okines, et al., “Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer,” New England Journal of Medicine 382 (2020): 597–609.

[138] G. Curigliano, V. Mueller, V. Borges, et al., “Tucatinib Versus Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer With and Without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis,” Annals of Oncology 33 (2022): 321–329.

[139] “Tucatinib Impresses in Breast Cancer,” Cancer Ddiscovery 10 (2020) 7.

[140] A. Schneeweiss, T. W. Park-Simon, J. Albanell, et al., “Phase Ib Study Evaluating Safety and Clinical Activity of the Anti-HER3 Antibody Lumretuzumab Combined With the Anti-HER2 Antibody Pertuzumab and Paclitaxel in HER3-Positive, HER2-Low Metastatic Breast Cancer,” Investigational New Drugs 36 (2018): 848–859.

[141] Z. Xu, D. Guo, Z. Jiang, et al., “Novel HER2-Targeting Antibody‒Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985),” European Journal of Medicinal Chemistry 183 (2019): 111682.

[142] D. Miricescu, A. Totan, S. Stanescu II, S. C. Badoiu, C. Stefani, and M. Greabu, “PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects,” International Journal of Molecular Sciences 22 (2020): 173.

[143] M. Guerin, K. Rezai, N. Isambert, et al., “PIKHER2: A Phase IB Study Evaluating buparlisib in Combination With lapatinib in Trastuzumab-Resistant HER2-Positive Advanced Breast Cancer,” European Journal of Cancer 86 (2017): 28–36.

[144] C. Saura, J. Bendell, G. Jerusalem, et al., “Phase Ib Study of Buparlisib Plus Trastuzumab in Patients With HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy,” Clinical Cancer Research 20 (2014): 1935–1945.

[145] S. Tolaney, H. Burris, E. Gartner, et al., “Phase I/II Study of pilaralisib (SAR245408) in Combination With Trastuzumab or Trastuzumab Plus Paclitaxel in Trastuzumab-Refractory HER2-Positive Metastatic Breast Cancer,” Breast Cancer Research and Treatment 149 (2015): 151–161.

[146] C. Hudis, C. Swanton, Y. Y. Janjigian, et al., “A Phase 1 Study Evaluating the Combination of an Allosteric AKT Inhibitor (MK-2206) and Trastuzumab in Patients With HER2-Positive Solid Tumors,” Breast Cancer Research 15 (2013): R110.

[147] S. A. Hurvitz, F. Andre, Z. Jiang, et al., “Combination of Everolimus With Trastuzumab Plus Paclitaxel as First-Line Treatment for Patients With HER2-Positive Advanced Breast Cancer (BOLERO-1): A Phase 3, Randomised, Double-Blind, Multicentre Trial,” Lancet Oncology 16 (2015): 816–829.

[148] C. A. Smith, A. A. Pollice, L. P. Gu, et al., “Correlations Among p53, Her-2/Neu, and Ras Overexpression and Aneuploidy by Multiparameter Flow Cytometry in Human Breast Cancer: Evidence for a Common Phenotypic Evolutionary Pattern in Infiltrating Ductal Carcinomas,” Clinical Cancer Research 6 (2000): 112–126.

[149] B. Milojkovic Kerklaan, V. Diéras, C. Le Tourneau, et al., “Phase I Study of lonafarnib (SCH66336) in Combination With Trastuzumab Plus Paclitaxel in Her2/Neu Overexpressing Breast Cancer: EORTC Study 16023,” Cancer Chemotheraphy and Pharmacology 71 (2013): 53–62.

[150] K. L. Reynolds, P. L. Bedard, S. H. Lee, et al., “A Phase I Open-Label Dose-Escalation Study of the Anti-HER3 Monoclonal Antibody LJM716 in Patients With Advanced Squamous Cell Carcinoma of the Esophagus or Head and Neck and HER2-Overexpressing Breast or Gastric Cancer,” BMC Cancer 17 (2017): 646.

[151] D. Sood, C. Kaur, N. Kumar, R. Kumar, and G. Singh, “Triple-Negative Breast Cancer: Challenges, Advances, and Promising Therapeutic Interventions,” Medical Oncology 42 (2025): 506.

[152] Y. Z. Jiang, D. Ma, C. Suo, et al., “Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies,” Cancer Cell 35 (2019): 428–440.e5.

[153] Y. Li, H. Zhang, Y. Merkher, et al., “Recent Advances in Therapeutic Strategies for Triple-Negative Breast Cancer,” Journal of Hematology & Oncology 15 (2022): 121.

[154] C. W. S. Tong, M. Wu, W. C. S. Cho, and K. K. W. To, “Recent Advances in the Treatment of Breast Cancer,” Frontiers in Oncology 8 (2018): 227.

[155] M. Robson, S. A. Im, E. Senkus, et al., “Olaparib for Metastatic Breast Cancer in Patients With a Germline BRCA Mutation,” New England Journal of Medicine 377 (2017): 523–533.

[156] A. N. J. Tutt, J. E. Garber, B. Kaufman, et al., “Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer,” New England Journal of Medicine 384 (2021): 2394–2405.

[157] J. K. Litton, H. S. Rugo, J. Ettl, et al., “Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation,” New England Journal of Medicine 379 (2018): 753–763.

[158] H. Li, J. Liu, Q. Ouyang, et al., “Fuzuloparib With or Without Apatinib in Patients With HER2-Negative Metastatic Breast Cancer With Germline BRCA1/2 Mutations (FABULOUS): Interim Analysis of a Multicentre, Three-Arm, Open-Label, Randomised, Phase 3 Trial,” Lancet Oncology 26 (2025): 1563–1574.

[159] A. Bardia, S. A. Hurvitz, S. M. Tolaney, et al., “Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer,” New England Journal of Medicine 384 (2021): 1529–1541.

[160] Y. Yin, Y. Fan, Q. Ouyang, et al., “Sacituzumab Tirumotecan in Previously Treated Metastatic Triple-Negative Breast Cancer: A Randomized Phase 3 Trial,” Nature Medicine 31 (2025): 1969–1975.

[161] J. Cortes, D. W. Cescon, H. S. Rugo, et al., “Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (KEYNOTE-355): A Randomised, Placebo-Controlled, Double-Blind, Phase 3 Clinical Trial,” Lancet 396 (2020): 1817–1828.

[162] P. Schmid, J. Cortes, R. Dent, et al., “Overall Survival With Pembrolizumab in Early-Stage Triple-Negative Breast Cancer,” New England Journal of Medicine 391 (2024): 1981–1991.

[163] Z. Jiang, Q. Ouyang, T. Sun, et al., “Toripalimab Plus Nab-Paclitaxel in Metastatic or Recurrent Triple-Negative Breast Cancer: A Randomized Phase 3 Trial,” Nature Medicine 30 (2024): 249–256.

[164] A. M. Gonzalez-Angulo, K. M. Timms, S. Liu, et al., “Incidence and Outcome of BRCA Mutations in Unselected Patients With Triple Receptor-Negative Breast Cancer,” Clinical Cancer Research 17 (2011): 1082–1089.

[165] M. A. Medina, G. Oza, A. Sharma, et al., “Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies,” International Journal of Environmental Research and Public Health 17 (2020): 2078.

[166] A. Jain, A. Barge, and C. N. Parris, “Combination Strategies With PARP Inhibitors in BRCA-Mutated Triple-Negative Breast Cancer: Overcoming Resistance Mechanisms,” Oncogene 44 (2025): 193–207.

[167] T. Helleday, “The Underlying Mechanism for the PARP and BRCA Synthetic Lethality: Clearing Up the Misunderstandings,” Molecular Oncology 5 (2011): 387–393.

[168] K. Hastak, E. Alli, and J. M. Ford, “Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-ribose) Polymerase Inhibition, Gemcitabine, and Cisplatin,” Cancer Research 70 (2010): 7970–7980.

[169] C. E. Geyer, J. E. Garber, R. D. Gelber, et al., “Overall Survival in the OlympiA Phase III Trial of Adjuvant Olaparib in Patients With Germline Pathogenic Variants in BRCA1/2 and High-Risk, Early Breast Cancer,” Annals of Oncology 33 (2022): 1250–1268.

[170] J. K. Litton, S. A. Hurvitz, L. A. Mina, et al., “Talazoparib Versus Chemotherapy in Patients With Germline BRCA1/2-Mutated HER2-Negative Advanced Breast Cancer: Final Overall Survival Results From the EMBRACA Trial,” Annals of Oncology 31 (2020): 1526–1535.

[171] T. A. Hopkins, W. B. Ainsworth, P. A. Ellis, et al., “PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow,” Molecular Cancer Research 17 (2019): 409–419.

[172] J. Murai, S. Y. Huang, B. B. Das, et al., “Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors,” Cancer Research 72 (2012): 5588–5599.

[173] V. Diéras, H. S. Han, B. Kaufman, et al., “Veliparib With Carboplatin and Paclitaxel in BRCA-Mutated Advanced Breast Cancer (BROCADE3): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial,” Lancet Oncology 21 (2020): 1269–1282.

[174] V. Diéras, H. S. Han, H. Wildiers, et al., “Veliparib With Carboplatin and Paclitaxel in BRCA-Mutated Advanced Breast Cancer (BROCADE3): Final Overall Survival Results From a Randomized Phase 3 Trial,” European Journal of Cancer 200 (2024): 113580.

[175] S. Wagener-Ryczek, S. Merkelbach-Bruse, and J. Siemanowski, “Biomarkers for Homologous Recombination Deficiency in Cancer,” Journal of Personalized Medicine 11 (2021): 612.

[176] E. Sakach, R. Sacks, and K. Kalinsky, “Trop-2 as a Therapeutic Target in Breast Cancer,” Cancers 14 (2022): 5936.

[177] M. Aslan, E. C. Hsu, F. J. Garcia-Marques, et al., “Oncogene-Mediated Metabolic Gene Signature Predicts Breast Cancer Outcome,” npj Breast Cancer 7 (2021): 141.

[178] L. M. Spring, S. M. Tolaney, G. Fell, et al., “Response-Guided Neoadjuvant Sacituzumab Govitecan for Localized Triple-Negative Breast Cancer: Results From the NeoSTAR Trial,” Annals of Oncology 35 (2024): 293–301.

[179] K. Kalinsky, J. R. Diamond, L. T. Vahdat, et al., “Sacituzumab Govitecan in Previously Treated Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Final Results from a Phase I/II, Single-Arm, Basket Trial,” Annals of Oncology 31 (2020): 1709–1718.

[180] P. Schmid, M. Oliveira, J. O'Shaughnessy, et al., “TROPION-Breast05: A Randomized Phase III Study of Dato-DXd With or Without Durvalumab Versus Chemotherapy Plus Pembrolizumab in Patients With PD-L1-High Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer,” Therapeutic Advances in Medical Oncology 17 (2025): 17588359251327992.

[181] A. A. Rose, A. A. Grosset, Z. Dong, et al., “Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer,” Clinical Cancer Research 16 (2010): 2147–2156.

[182] D. A. Yardley, R. Weaver, M. E. Melisko, et al., “EMERGE: A Randomized Phase II Study of the Antibody‒Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer,” Journal of Clinical Oncology 33 (2015): 1609–1619.

[183] L. T. Vahdat, P. Schmid, A. Forero-Torres, et al., “Glembatumumab Vedotin for Patients With Metastatic, gpNMB Overexpressing, Triple-Negative Breast Cancer (“METRIC”): A Randomized Multicenter Study,” npj Breast Cancer 7 (2021): 57.

[184] M. Keskinkilic and R. Sacks, “Antibody‒Drug Conjugates in Triple Negative Breast Cancer,” Clinical Breast Cancer 24 (2024): 163–174.

[185] R. Salgado, C. Denkert, S. Demaria, et al., “The Evaluation of Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer: Recommendations by an International TILs Working Group 2014,” Annals of Oncology 26 (2015): 259–271.

[186] R. K. Beckers, C. I. Selinger, R. Vilain, et al., “Programmed Death Ligand 1 Expression in Triple-Negative Breast Cancer Is Associated With Tumour-Infiltrating Lymphocytes and Improved Outcome,” Histopathology 69 (2016): 25–34.

[187] L. A. Emens, C. Cruz, J. P. Eder, et al., “Long-Term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study,” JAMA Oncology 5 (2019): 74–82.

[188] P. Schmid, S. Adams, H. S. Rugo, et al., “Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer,” New England Journal of Medicine 379 (2018): 2108–2121.

[189] E. A. Mittendorf, H. Zhang, C. H. Barrios, et al., “Neoadjuvant Atezolizumab in Combination With Sequential Nab-Paclitaxel and Anthracycline-Based Chemotherapy Versus Placebo and Chemotherapy in Patients With Early-Stage Triple-Negative Breast Cancer (IMpassion031): A Randomised, Double-Blind, Phase 3 Trial,” Lancet 396 (2020): 1090–1100.

[190] D. Miles, J. Gligorov, F. André, et al., “Primary Results from IMpassion131, a Double-Blind, Placebo-Controlled, Randomised Phase III Trial of First-Line Paclitaxel With or Without Atezolizumab for Unresectable Locally Advanced/Metastatic Triple-Negative Breast Cancer,” Annals of Oncology 32 (2021): 994–1004.

[191] M. Nakhjavani, J. E. Hardingham, H. M. Palethorpe, T. J. Price, and A. R. Townsend, “Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer,” Journal of Breast Cancer 22 (2019): 341–361.

[192] C. A. Santa-Maria, T. Kato, J. H. Park, et al., “A Pilot Study of Durvalumab and Tremelimumab and Immunogenomic Dynamics in Metastatic Breast Cancer,” Oncotarget 9 (2018): 18985–18996.

[193] Q. Li, J. Liu, Q. Zhang, et al., “The Anti-PD-L1/CTLA-4 Bispecific Antibody KN046 in Combination With Nab-Paclitaxel in First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Multicenter Phase II Trial,” Nature Communications 15 (2024): 1015.

[194] C. H. June, R. S. O'Connor, O. U. Kawalekar, S. Ghassemi, and M. C. Milone, “CAR T Cell Immunotherapy for Human Cancer,” Science 359 (2018): 1361–1365.

[195] N. Stergiou, N. Gaidzik, A. S. Heimes, et al., “Reduced Breast Tumor Growth After Immunization With a Tumor-Restricted MUC1 Glycopeptide Conjugated to Tetanus Toxoid,” Cancer Immunology Research 7 (2019): 113–122.

[196] L. Xia, Z. Zheng, J. Y. Liu, et al., “Targeting Triple-Negative Breast Cancer With Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition,” Cancer Immunology Research 9 (2021): 707–722.

[197] B. K. Linderholm, H. Hellborg, U. Johansson, et al., “Significantly Higher Levels of Vascular Endothelial Growth Factor (VEGF) and Shorter Survival Times for Patients With Primary Operable Triple-Negative Breast Cancer,” Annals of Oncology 20 (2009): 1639–1646.

[198] D. W. Miles, A. Chan, L. Y. Dirix, et al., “Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer,” Journal of Clinical Oncology 28 (2010): 3239–3247.

[199] N. J. Robert, V. Diéras, J. Glaspy, et al., “RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer,” Journal of Clinical Oncology 29 (2011): 1252–1260.

[200] H. D. Bear, G. Tang, P. Rastogi, et al., “Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer,” New England Journal of Medicine 366 (2012): 310–320.

[201] D. Cameron, J. Brown, R. Dent, et al., “Adjuvant Bevacizumab-Containing Therapy in Triple-Negative Breast Cancer (BEATRICE): Primary Results of a Randomised, Phase 3 Trial,” Lancet Oncology 14 (2013): 933–942.

[202] N. M. Ayoub, S. K. Jaradat, K. M. Al-Shami, and A. E. Alkhalifa, “Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches,” Frontiers in Pharmacology 13 (2022): 838133.

[203] V. N. Barton, N. C. D'Amato, M. A. Gordon, et al., “Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide In Vivo,” Molecular Cancer Therapeutics 14 (2015): 769–778.

[204] S. Vtorushin, A. Dulesova, and N. Krakhmal, “Luminal Androgen Receptor (LAR) Subtype of Triple-Negative Breast Cancer: Molecular, Morphological, and Clinical Features,” Journal of Zhejiang University-SCIENCE B 23 (2022): 617–624.

[205] M. Rampurwala, K. B. Wisinski, and R. O'Regan, “Role of the Androgen Receptor in Triple-Negative Breast Cancer,” Clinical Advances in Hematology & Oncology 14 (2016): 186–193.

[206] T. A. Traina, K. Miller, D. A. Yardley, et al., “Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer,” Journal of Clinical Oncology 36 (2018): 884–890.

[207] B. Lim, S. Seth, C. Yam, et al., “Phase 2 Study of Neoadjuvant Enzalutamide and Paclitaxel for Luminal Androgen Receptor-Enriched TNBC: Trial Results and Insights Into “ARness”,” Cell Reports Medicine 5 (2024): 101595.

[208] Y. Yuan, J. S. Lee, S. E. Yost, et al., “A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients With Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer,” Oncologist 26 (2021): 99–e217.

[209] A. M. Ali, J. A. K. Ansari, N. M. A. El-Aziz, et al., “Triple Negative Breast Cancer: A Tale of Two Decades,” Anti-Cancer Agents in Medicinal Chemistry 17 (2017): 491–499.

[210] J. Baselga, P. Gómez, R. Greil, et al., “Randomized Phase II Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer,” Journal of Clinical Oncology 31 (2013): 2586–2592.

[211] L. A. Carey, H. S. Rugo, P. K. Marcom, et al., “TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer,” Journal of Clinical Oncology 30 (2012): 2615–2623.

[212] F. Tomao, A. Papa, E. Zaccarelli, et al., “Triple-Negative Breast Cancer: New Perspectives for Targeted Therapies,” OncoTargets and Therapy 8 (2015): 177–193.

[213] D. Mehlich and A. A. Marusiak, “Kinase Inhibitors for Precision Therapy of Triple-Negative Breast Cancer: Progress, Challenges, and New Perspectives on Targeting This Heterogeneous Disease,” Cancer Letters 547 (2022): 215775.

[214] I. Schlam, R. Moges, S. Morganti, S. M. Tolaney, and P. Tarantino, “Next-Generation Antibody‒Drug Conjugates for Breast Cancer: Moving Beyond HER2 and TROP2,” Critical Reviews in Oncology/Hematology 190 (2023): 104090.

[215] R. Zhu, X. Tang, and H. Zhang, “Targeted Protein Degradation: From Basic Science to Therapeutic Applications,” ACS Chemical Biology 20 (2025): 979–982.

[216] Y. Qiu, Y. Shi, Z. Chao, X. Zhu, Y. Chen, and L. Lu, “Recent Advances of Antibody‒Drug Conjugates in Treating Breast Cancer With Different HER2 Status,” Therapeutic Advances in Medical Oncology 17 (2025): 17588359241311379.

[217] X. Gao, T. Bu, W. Wang, and Y. Xu, “Comparative Analysis and Future Prospects of Human Epidermal Growth Factor Receptor 2 (HER2) and Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted Antibody‒Drug Conjugates in Breast Cancer Treatment,” Breast Cancer 16 (2024): 621–630.

[218] T. A. O'Meara, P. Tarantino, S. Morganti, I. Schlam, A. C. Garrido-Castro, and S. M. Tolaney, “Antibody‒Drug Conjugates in Breast Cancer: The Road Towards Biologically-Informed Selection and Sequencing,” Current Oncology Reports 27 (2025): 68–79.

[219] H. S. Rugo, A. Bardia, F. Marmé, et al., “Overall Survival With Sacituzumab Govitecan in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer (TROPiCS-02): A Randomised, Open-Label, Multicentre, Phase 3 Trial,” Lancet 402 (2023): 1423–1433.

[220] T. Sirek, K. Król-Jatręga, P. Borawski, et al., “Distinct mRNA Expression Profiles and miRNA Regulators of the PI3K/AKT/mTOR Pathway in Breast Cancer: Insights Into Tumor Progression and Therapeutic Targets,” Frontiers in Oncology 14 (2024): 1515387.

[221] S. Chandarlapaty, R. A. Sakr, D. Giri, et al., “Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer,” Clinical Cancer Research 18 (2012): 6784–6791.

[222] K. Zhu, Y. Wu, P. He, et al., “PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer,” Cells 11 (2022): 2508.

[223] H. P. Zhang, R. Y. Jiang, J. Y. Zhu, et al., “PI3K/AKT/mTOR Signaling Pathway: An Important Driver and Therapeutic Target in Triple-Negative Breast Cancer,” Breast Cancer 31 (2024): 539–551.

[224] F. Lin, S. Yin, Z. Zhang, et al., “Multimodal Targeting Chimeras Enable Integrated Immunotherapy Leveraging Tumor-Immune Microenvironment,” Cell 187 (2024): 7470–7491.e32.

[225] Á. Szöőr, G. Tóth, B. Zsebik, et al., “Trastuzumab Derived HER2-Specific CARs for the Treatment of Trastuzumab-Resistant Breast Cancer: CAR T Cells Penetrate and Eradicate Tumors That Are Not Accessible to Antibodies,” Cancer Letters 484 (2020): 1–8.

[226] R. Zhou, M. Yazdanifar, L. D. Roy, et al., “CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth,” Frontiers in Immunology 10 (2019): 1149.

[227] Y. Wang, J. Shi, M. Xin, A. R. Kahkoska, J. Wang, and Z. Gu, “Cell-Drug Conjugates,” Nature Biomedical Engineering 8 (2024): 1347–1365.

[228] S. M. Cheal, S. K. Chung, B. A. Vaughn, N. V. Cheung, and S. M. Larson, “Pretargeting: A Path Forward for Radioimmunotherapy,” Journal of Nuclear Medicine 63 (2022): 1302–1315.

[229] O. Saatci, K. T. Huynh-Dam, and O. Sahin, “Endocrine Resistance in Breast Cancer: From Molecular Mechanisms to Therapeutic Strategies,” Journal of Molecular Medicine 99 (2021): 1691–1710.

[230] C. Vernieri, M. Milano, M. Brambilla, et al., “Resistance Mechanisms to Anti-HER2 Therapies in HER2-Positive Breast Cancer: Current Knowledge, New Research Directions and Therapeutic Perspectives,” Critical Reviews in Oncology/Hematology 139 (2019): 53–66.

[231] K. Mandal, G. K. Barik, and M. K. Santra, “Overcoming Resistance to Anti-PD-L1 Immunotherapy: Mechanisms, Combination Strategies, and Future Directions,” Molecular Cancer 24 (2025): 246.

[232] M. Kundu, R. Butti, V. K. Panda, et al., “Modulation of the Tumor Microenvironment and Mechanism of Immunotherapy-Based Drug Resistance in Breast Cancer,” Molecular Cancer 23 (2024): 92.

[233] X. Fu, P. Li, Q. Zhou, et al., “Mechanism of PARP Inhibitor Resistance and Potential Overcoming Strategies,” Genes & Diseases 11 (2024): 306–320.

[234] B. Wang, J. M. Rosano, R. Cheheltani, M. P. Achary, and M. F. Kiani, “Towards a Targeted Multi-Drug Delivery Approach to Improve Therapeutic Efficacy in Breast Cancer,” Expert Opinion on Drug Delivery 7 (2010): 1159–1173.

[235] T. A. Yap, E. Hamilton, T. Bauer, et al., “Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes,” JCO Precision Oncology 6 (2022): e2100456.

[236] M. Baksh, B. Mahajan, M. M. Dufresne, et al., “Circulating Tumor DNA for Breast Cancer: Review of Active Clinical Trials,” Cancer Treatment and Research Communications 32 (2022): 100609.

[237] I. E. Krop, N. Masuda, T. Mukohara, et al., “Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial,” Journal of Clinical Oncology 41 (2023): 5550–5560.

[238] A. M. Holder, A. Dedeilia, K. Sierra-Davidson, et al., “Defining Clinically Useful Biomarkers of Immune Checkpoint Inhibitors in Solid Tumours,” Nature Reviews Cancer 24 (2024): 498–512.

[239] W. Jelski, S. Okrasinska, and B. Mroczko, “microRNAs as Biomarkers of Breast Cancer,” International Journal of Molecular Sciences 26 (2025): 4395.

[240] B. Abdullaev, S. A. Rasyid, E. Ali, et al., “Effective Exosomes in Breast Cancer: Focusing on Diagnosis and Treatment of Cancer Progression,” Pathology, Research and Practice 253 (2024): 154995.

[241] P. Schmid, J. Cortes, L. Pusztai, et al., “Pembrolizumab for Early Triple-Negative Breast Cancer,” New England Journal of Medicine 382 (2020): 810–821.

[242] Y. Hou, H. Nitta, and Z. Li, “HER2 Intratumoral Heterogeneity in Breast Cancer, an Evolving Concept,” Cancers 15 (2023): 2664.

[243] R. Tébar-Martínez, J. Martín-Arana, F. Gimeno-Valiente, N. Tarazona, P. Rentero-Garrido, and A. Cervantes, “Strategies for Improving Detection of Circulating Tumor DNA Using Next Generation Sequencing,” Cancer Treatment Reviews 119 (2023): 102595.

[244] A. Witz, J. Dardare, M. Betz, et al., “Homologous Recombination Deficiency (HRD) Testing Landscape: Clinical Applications and Technical Validation for Routine Diagnostics,” Biomarker Research 13 (2025): 31.

[245] F. P. Kraja, V. B. Jurisic, A. Hromić-Jahjefendić, et al., “Tumor-Infiltrating Lymphocytes in Cancer Immunotherapy: From Chemotactic Recruitment to Translational Modeling,” Frontiers in Immunology 16 (2025): 1601773.

[246] E. El Gazzah, S. Parker, and M. Pierobon, “Multi-Omic Profiling in Breast Cancer: Utility for Advancing Diagnostics and Clinical Care,” Expert Review of Molecular Diagnostics 25 (2025): 165–181.

[247] D. P. Narvaez and D. W. Cescon, “Navigating Treatment Sequencing in Advanced HR+/HER2− Breast Cancer After CDK4/6 Inhibitors: Biomarker-Driven Strategies and Emerging Therapies,” International Journal of Molecular Sciences 26 (2025): 10366.

[248] R. Mishra, H. Patel, S. Alanazi, M. K. Kilroy, and J. T. Garrett, “PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects,” International Journal of Molecular Sciences 22 (2021): 3464.

[249] A. S. Alanazi, A. A. Alanazi, A. Alanizi, et al., “Trastuzumab Deruxtecan-Associated Interstitial Lung Disease: Real-World Insights From a Tertiary Care Center,” Current Oncology 32 (2025): 575.

[250] H. S. Rugo, S. M. Tolaney, D. Loirat, et al., “Safety Analyses From the Phase 3 ASCENT Trial of Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer,” npj Breast Cancer 8 (2022): 98.

[251] M. Z. Wojtukiewicz, M. M. Rek, K. Karpowicz, et al., “Inhibitors of Immune Checkpoints-PD-1, PD-L1, CTLA-4-New Opportunities for Cancer Patients and a New Challenge for Internists and General Practitioners,” Cancer and Metastasis Reviews 40 (2021): 949–982.

[252] B. Liu, H. Zhou, L. Tan, K. T. H. Siu, and X. Y. Guan, “Exploring Treatment Options in Cancer: Tumor Treatment Strategies,” Signal Transduction and Targeted Therapy 9 (2024): 175.

[253] M. J. Hadfield, B. A. Carneiro, and L. Cheng, “Targeted Therapeutic Approaches for the Treatment of Cancer: The Future Is Bright,” Journal of Personalized Medicine 15 (2025): 141.

[254] M. D. Chamberlin, E. B. Bernhardt, and T. W. Miller, “Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer,” Journal of Cellular Biochemistry 117 (2016): 2454–2463.

[255] L. Xiang, J. Rao, J. Yuan, T. Xie, and H. Yan, “Single-Cell RNA-Sequencing: Opening New Horizons for Breast Cancer Research,” International Journal of Molecular Sciences 25 (2024): 9482.

[256] Y. A. DeClerck, “Envision the Future of Precision Medicine in Pediatric Cancer,” Cancer Cell 42 (2024): 177–179.

[257] P. Chen, X. Zhang, R. Ding, et al., “Patient-Derived Organoids Can Guide Personalized-Therapies for Patients With Advanced Breast Cancer,” Advanced Science 8 (2021): e2101176.

[258] M. Panagopoulou, M. Esteller, and E. Chatzaki, “Circulating Cell-Free DNA in Breast Cancer: Searching for Hidden Information Towards Precision Medicine,” Cancers 13 (2021): 728.

[259] M. Puccetti, M. Pariano, A. Schoubben, S. Giovagnoli, and M. Ricci, “Biologics, Theranostics, and Personalized Medicine in Drug Delivery Systems,” Pharmacological Research 201 (2024): 107086.

[260] Y. Wang, C. Guo, and W. Li, “Artificial Intelligence in Antibody-Drug Conjugate Development,” Trends in Pharmacological Sciences 46, no. 12 (2025): 1209–1223.

[261] R. Bansal, T. Adeyelu, A. Elliott, et al., “Genomic and Transcriptomic Landscape of HER2-Low Breast Cancer,” Breast Cancer Research and Treatment 209 (2025): 323–330.

[262] S. Oda, Y. Tokuda, Y. Suzuki, et al., “Integrative Radiogenomics Using MRI Radiomics and Microarray Gene Expression Analysis to Predict Pathological Complete Response in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy,” Cureus 17 (2025): e86287.

[263] R. Wang, Q. Liu, W. You, H. Wang, and Y. Chen, “A Transformer-Based Deep Learning Survival Prediction Model and an Explainable XGBoost Anti-PD-1/PD-L1 Outcome Prediction Model Based on the cGAS-STING-Centered Pathways in Hepatocellular Carcinoma,” Briefings in Bioinformatics 26 (2024): bbae686.

[264] S. P. Somashekhar, M. J. Sepúlveda, S. Puglielli, et al., “Watson for Oncology and Breast Cancer Treatment Recommendations: Agreement With an Expert Multidisciplinary Tumor Board,” Annals of Oncology 29 (2018): 418–423.

[265] Y. Gu, R. Yang, Y. Zhang, et al., “Molecular Mechanisms and Therapeutic Strategies in Overcoming Chemotherapy Resistance in Cancer,” Molecular Biomedicine 6 (2025): 2.

[266] S. Marletta, A. Rizzo, G. Spoto, and L. Falzone, “Predictive and Prognostic Biomarkers in Cancer: Towards the Precision Medicine Era,” Exploration of Targeted Anti-tumor Therapy 5 (2024): 1321–1325.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.